[go: up one dir, main page]

WO2009030088A1 - Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline - Google Patents

Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline Download PDF

Info

Publication number
WO2009030088A1
WO2009030088A1 PCT/CN2007/070629 CN2007070629W WO2009030088A1 WO 2009030088 A1 WO2009030088 A1 WO 2009030088A1 CN 2007070629 W CN2007070629 W CN 2007070629W WO 2009030088 A1 WO2009030088 A1 WO 2009030088A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
protein
cam
camkiina
kiina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2007/070629
Other languages
English (en)
Chinese (zh)
Inventor
Nan Li
Xuetao Cao
Chunmei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Second Military Medical University SMMU
Original Assignee
Second Military Medical University SMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Military Medical University SMMU filed Critical Second Military Medical University SMMU
Priority to PCT/CN2007/070629 priority Critical patent/WO2009030088A1/fr
Publication of WO2009030088A1 publication Critical patent/WO2009030088A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention belongs to the fields of biotechnology and medicine, and in particular, the present invention relates to a human calcium/Calmodulin-Dependent Protein Kinase II Inhibitor a (CaM-KIINa) and a coding sequence thereof.
  • CaM-KIINa human calcium/Calmodulin-Dependent Protein Kinase II Inhibitor a
  • Human CaMKIINa is highly expressed in normal and highly differentiated colon adenocarcinoma and has an inhibitory effect on the growth of colon adenocarcinoma cells. Background technique
  • Calcium ion is an important second messenger and plays an important role in cell growth and differentiation.
  • CaMKII is a multifunctional serine/threonine protein kinase widely distributed in various organ tissues, mainly in nervous tissues. It is especially high in the brain and can reach 1-2% of total protein. It can phosphorylate more than 40 protein molecules with important physiological functions in vivo including enzymes, ion channels, transcription factors, etc.; CaMKII can regulate the metabolism of carbohydrates, amino acids, fats, synthesis and release of neurotransmitters, transcription factors Transcription, cytoskeletal construction, cell cycle progression, DNA damage repair, etc. Physiological and pathological processes. In recent years, some studies have suggested that CaMKII plays an important role in the growth and differentiation of cells. It is also believed that CaMKII is an essential molecule for the smooth progression of the cell cycle.
  • CaMKII inhibitors are mainly divided into three categories: inhibitors of chemical synthesis (KN-62, KN-93, KN-92), biosynthesis inhibitory polypeptides (AIP), and inhibitory proteins endogenously expressed by cells.
  • the mechanism of action of chemical inhibitors is mainly through the binding of Ca 2+ /CaM binding sites, preventing the binding of Ca 2+ /CaM to CaMKII, making CaMKII inactivated by phosphorylation, and specifically inhibiting the activity of CaMKII. .
  • the endogenous inhibitory protein has a structure similar to the CaMKII self-regulating region, which interacts with the catalytic domain to block the binding of CaMKII and its phosphorylated substrate. Inhibition of CaMKII activity blocks the phosphorylation of its substrate by CaMKII or regulates the transcription of certain genes, leading to abnormal cell functions such as cell cycle regulation and DNA damage repair, affecting the normal growth process of cells. It has been reported that chemical CaMKII inhibitors can induce apoptosis, necrosis and growth retardation in tumor cells, and this aspect can provide new strategies and directions for clinical tumor treatment.
  • Rat CaMKIINoc is specifically distributed in the brain, while rat CaMKIINP has specific high expression in both brain and testis.
  • Human CaMKIINP is in the heart, skeletal muscle, Liver, kidney, small intestine, placenta, etc. are expressed.
  • Human CaMKIINoc has high expression in brain, kidney, small intestine and colon, and low expression in placenta, heart, pancreas, spleen and testis, but no expression in skeletal muscle.
  • Differences in endogenous CaMKII inhibitory protein expression profiles suggest that these proteins may play different roles in different tissues and organs.
  • the specific expression of CaMKII inhibitory protein and the state of cell growth have not been reported so far, which is the relationship between tumor cell growth.
  • the object of the present invention is to provide a novel human calcium/calmodulin-dependent protein kinase II inhibitory protein.
  • CaMKIINa protein as well as fragments, analogs and derivatives thereof.
  • Another object of the invention is to provide the use of a CaMKIINa polypeptide and its coding sequence.
  • composition is also useful for treating colonic adenocarcinoma.
  • the human CaMKIINa protein is selected from the group consisting of:
  • a fusion protein of a CaMKIINa protein comprising the amino acid sequence of SEQ ID NO: 2 and having an inhibitory function on the growth of colonic adenocarcinoma cells.
  • the coding sequence is a nucleotide sequence encoding the human CaMKIINa protein of the above 0), (b) or (c). More preferably, the coding sequence is selected from the group consisting of:
  • the composition is a pharmaceutical composition.
  • CaM-KIINa or a coding sequence thereof is also used to prepare a reagent or kit for detecting the degree of differentiation of colon adenocarcinoma.
  • a method of screening for an agonist of a CaM-KIINa polypeptide comprising the steps of: (a) providing a test group and a control group, wherein the control group is a culture system of a tumor cell expressing a CaMKIINa polypeptide or a culture system of a tumor cell to which a CaMKIINa polypeptide is added, the test group is added with a test substance a culture system of a tumor cell expressing a CaMKIINa polypeptide, or a culture system of a tumor cell to which a test substance and a CaMKIINa polypeptide are added;
  • the growth rate of the tumor cells in the test group was smaller than that of the control group, indicating that the test substance was an agonist of the CaM-KIINa polypeptide.
  • the tumor cell is a colon adenocarcinoma cell.
  • the method further comprises the steps of: (c) screening the obtained agonist of the CaM-KIINa polypeptide to further test its ability to inhibit tumor cell growth, thereby selecting a potential treatment for inhibiting tumor cell growth. Agent.
  • a method for inhibiting the growth of colonic adenocarcinoma cells in vitro comprising the steps of: adding a human calcium/calmodulin-dependent protein kinase II inhibitory protein a, ie, CaM, to a colonic adenocarcinoma cell culture system -KIINa o
  • a human calcium/calmodulin-dependent protein kinase II inhibitory protein a, CaM-KIINa or a coding sequence thereof for use in the preparation of a reagent for detecting the degree of differentiation of colon adenocarcinoma Or kit.
  • the reagent is an antibody, a primer or a probe (such as a primer pair that specifically amplifies a CaM-KIINa gene or transcript or a probe that specifically binds to a CaM-KIINa gene or transcript) ;).
  • the kit comprises an antibody that specifically binds to a CaM-KIINa polypeptide, a primer pair that specifically amplifies a CaM-KIINa gene or transcript, or specifically binds to a CaM-KIINa gene or transcription. Probe for the object.
  • Figure 1 shows the Western blot identification of anti-CaMKIINa antibody specificity.
  • Figure 2 shows the eukaryotic recombinant expression vector of human CaMKIINa transfected into human tumor cells expressing CaMKIINa Western blot analysis of the protein.
  • FIG. 3 shows that human CaMKIINa protein overexpression of the present invention inhibits tumor cell proliferation.
  • Figure 4 shows the inhibitory effect of CaMKIINoc protein on tumor growth in vivo.
  • CaM-KIINa has an inhibitory effect on the growth of colonic adenocarcinoma cells, and thus can be used as a candidate substance and target for the treatment of colon adenocarcinoma.
  • CaM-KIINa is highly expressed in normal colon tissues and highly differentiated colon adenocarcinoma tissues, and is highly expressed in malignant colon adenocarcinoma tissues with low degree of differentiation, and thus can be used as an auxiliary for indicating the degree of differentiation of colon adenocarcinoma. The marker is detected.
  • the CaMKIINa protein is selectively highly expressed in normal colon tissues and colon cancer adenocarcinoma tissues with a higher degree of differentiation, and is less expressed in a less differentiated malignant colon adenocarcinoma tissue.
  • CaMKIIN ⁇ inhibits the growth of LoVo colonic adenocarcinoma cells in vitro, and can significantly inhibit the growth of LoVo tumors inoculated subcutaneously in nude mice.
  • Selective expression of CaMKIINa in colon adenocarcinoma and overexpression of CaMKIINa inhibit colon cell growth of colon adenocarcinoma.
  • CaM-KIINa protein CaM-KIINa protein
  • CaM-KIINa protein CaM-KIINa protein
  • calcium ions/calcium A protein or polypeptide that regulates a protein kinase II inhibitory protein a amino acid sequence (SEQ ID NO: 2). They include CaM-KIINa polypeptides with or without the initial methionine.
  • isolated means that the substance is separated from its original environment (if it is a natural substance, the original environment is the natural environment).
  • the polynucleotides and polypeptides in the natural state in living cells are not isolated and purified, but the same polynucleotide or polypeptide is separated and purified, such as from other substances existing in the natural state. .
  • isolated CaM-KIINa protein or polypeptide means that the CaM-KIINa protein is substantially free of other proteins, lipids, carbohydrates or other substances with which it is naturally associated. Those skilled in the art can purify the CaM-KIINa protein using standard protein purification techniques. A substantially pure polypeptide produces a single major band on a non-reducing polyacrylamide gel.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, a synthetic polypeptide, preferably a recombinant polypeptide.
  • the polypeptide may be a naturally purified product, or a chemically synthesized product, or produced by recombinant techniques from prokaryotic or eukaryotic hosts (e.g., bacteria, yeast, higher plant, insect, and mammalian cells;
  • the polypeptide of the invention may be glycosylated, or may be non-glycosylated, depending on the host used in the recombinant production protocol.
  • Polypeptides of the invention may also or may not include an initial methionine residue.
  • the invention also encompasses fragments, derivatives and analogs of the human CaM-KIINa protein.
  • fragment refers to a polypeptide that substantially retains the same biological function or activity of the native human CaM-KIINa protein of the invention.
  • the polypeptide fragment, derivative or analog of the present invention may be a polypeptide having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues;), and such substituted amino acid residues may Is not also encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a mature polypeptide and another compound (such as a compound that extends the half-life of the polypeptide, such as poly Ethylene glycol;) a polypeptide formed by fusion, or (iv) a polypeptide formed by fusion of an additional amino acid sequence to the polypeptide sequence (such as a leader or secretion sequence or a sequence or proprotein sequence used to purify the polypeptide, or A fusion protein for the formation of an antigenic IgG fragment;).
  • conservative amino acid residues preferably conservative amino acid residues;
  • substituted amino acid residues may Is not also encoded by the genetic code
  • human CaM-KIINa protein means having the activity of human CaM-KIINa protein.
  • a polypeptide of the sequence of SEQ ID NO. also encompasses variant forms of the sequence of SEQ ID NO. 2 that have the same function as the human CaM-KIINa protein. These variants include, but are not limited to, several (usually 1-20, more preferably 1-10, optimally 1-5) amino acid deletions, insertions and/or substitutions, and at the C-terminus and / or N-terminal addition of one or several (; usually less than 20, preferably less than 10, more preferably less than 5) amino acids. For example, in the field, similar or similar amino acids When substituted, it usually does not change the function of the protein. For example, the addition of one or several amino acids at the C-terminus and / or N-terminus usually does not alter the function of the protein.
  • the term also includes active fragments of the human CaM-KIINa protein. And active derivatives.
  • Variants of the polypeptide include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, DNA encoded by DNA that hybridizes to human CaM-KIINa DNA under high or low stringency conditions Protein, and polypeptide or protein obtained using an antiserum against human CaM-KIINa protein.
  • the invention also provides other polypeptides, such as fusion proteins comprising the human CaM-KIINa protein or a fragment thereof.
  • the present invention also encompasses soluble fragments of the human CaM-KIINa protein.
  • the fragment has at least about 10 contiguous amino acids of the human CaM-KIINa protein sequence, typically at least about 30 contiguous amino acids, preferably at least about 50 contiguous amino acids, and most preferably at least about 70 contiguous amino acids.
  • the invention also provides analogs of the human CaM-KIINa protein or polypeptide.
  • the difference between these analogs and the native human CaM-KIINa protein may be a difference in amino acid sequence or a modification that does not affect the sequence. Formal differences, or both.
  • These polypeptides include natural or induced genetic variants. Induced variants can be obtained by a variety of techniques, such as random mutagenesis by irradiation or exposure to a mutagen, or by site-directed mutagenesis or other techniques known to molecular biology.
  • Analogs also include analogs having residues other than the native L-amino acid (e.g., D-amino acids), as well as analogs having non-naturally occurring or synthetic amino acids (e.g., beta, ⁇ -amino acids). It is to be understood that the polypeptide of the present invention is not limited to the representative polypeptides exemplified above.
  • Modifications include chemically derivatized forms of the polypeptide, such as acetylation or carboxylation, in vivo or in vitro. Modifications also include glycosylation, such as those produced by glycosylation modifications in the synthesis and processing of the polypeptide or in further processing steps. Such modification can be accomplished by exposing the polypeptide to an enzyme that performs glycosylation, such as a mammalian glycosylation enzyme or a deglycosylation enzyme. Modified forms also include sequences having phosphorylated amino acid residues such as phosphotyrosine, phosphoserine, phosphothreonine. Also included are polypeptides that have been modified to enhance their resistance to proteolytic properties or to optimize solubility properties.
  • human CaM-KIINa protein conservative variant polypeptide means up to 10, preferably up to 8, more preferably up to 5, optimally compared to the amino acid sequence of SEQ ID NO: 2. Up to 3 amino acids are replaced by amino acids of similar or similar nature to form a polypeptide.
  • CaM-KIINa coding sequence refers to a nucleotide sequence that encodes a CaM-KIINa protein, or an active fragment thereof, a fusion protein, a derivative, and the like.
  • the polynucleotide of the present invention may be in the form of DNA or RNA.
  • the DNA form includes cDNA, genomic DNA or synthetic DNA.
  • DNA can be single-stranded or double-stranded.
  • the DNA can be a coding strand or a non-coding strand.
  • the coding region sequence encoding the mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1, or a degenerate variant.
  • degenerate variant in the present invention refers to a nucleic acid sequence which encodes a protein having SEQ ID NO: 2 but differs from the coding region sequence shown in SEQ ID NO: 1.
  • Polynucleotide encoding the mature polypeptide of SEQ ID NO: 2 includes: a coding sequence encoding only the mature polypeptide; a coding sequence for the mature polypeptide and various additional coding sequences; a coding sequence for the mature polypeptide (; and optionally an additional coding sequence) And non-coding sequences.
  • polynucleotide encoding a polypeptide may be a polynucleotide comprising the polypeptide, or may be a polynucleotide further comprising additional coding and/or non-coding sequences.
  • the invention also relates to variants of the above polynucleotides which encode fragments, analogs and derivatives of polypeptides or polypeptides having the same amino acid sequence as the invention.
  • Variants of this polynucleotide may be naturally occurring Allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
  • an allelic variant is an alternative form of a polynucleotide which may be a substitution, deletion or insertion of one or more nucleotides, but does not substantially alter the function of the polypeptide encoded thereby. .
  • the invention also relates to hybridization to the sequences described above and having at least 50% between the two sequences, preferably at least
  • hybridize means: (1) hybridization and elution at a lower ionic strength and higher temperature, such as 0.2 X SSC, 0.1% SDS, 60 ° C ; or (2) hybridization Adding a denaturant such as 50% (v/v) formamide, 0.1% calf serum / 0.1% Ficoll, 42 ° C, etc.; or (3) at least 90% identity between the two sequences More preferably, hybridization occurs more than 95%.
  • the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide of SEQ ID NO: 2.
  • nucleic acid fragments that hybridize to the sequences described above.
  • a "nucleic acid fragment” is at least 15 nucleotides in length, preferably at least 30 nucleotides, more preferably at least 50 nucleotides, and most preferably at least 100 nucleotides or more.
  • Nucleic acid fragments can be used in nucleic acid amplification techniques (such as PCR) to identify and/or isolate polynucleotides encoding CaM-KIINa proteins.
  • the polypeptides and polynucleotides of the invention are preferably provided in isolated form, more preferably purified to homogeneity.
  • the human CaM-KIINa full-length nucleotide sequence of the present invention or a fragment thereof can be usually obtained by a PCR amplification method, a recombinant method or a synthetic method.
  • primers can be designed in accordance with the disclosed nucleotide sequences, particularly open reading frame sequences, and can be prepared using commercially available cDNA libraries or conventional methods known to those skilled in the art.
  • the library is used as a template to amplify the relevant sequences. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then the amplified fragments are spliced together in the correct order.
  • the recombination method can be used to obtain the relevant sequences in large quantities. This is usually done by cloning it into a vector, transferring it to a cell, and then isolating the relevant sequence from the proliferated host cell by conventional methods.
  • the invention also relates to vectors comprising the polynucleotides of the invention, and host cells genetically engineered using the vector of the invention or the CaM-KIINa protein coding sequence, and methods of producing the polypeptides of the invention by recombinant techniques.
  • the polynucleotide sequence of the present invention can be used to express or produce a recombinant CaM-KIINa protein by conventional recombinant DNA techniques. Generally there are the following steps:
  • the invention also relates to agonists of the CaMKIINa polypeptide.
  • an agonist of a CaMKIINa polypeptide refers to a substance that enhances, or enhances, the activity or expression of a CaMKIINa polypeptide.
  • the agonist can be used to promote the inhibition of the growth of colonic adenocarcinoma cells by the CaMKIINa polypeptide.
  • the present invention also encompasses polyclonal antibodies and monoclonal antibodies, particularly monoclonal antibodies, which are specific for human CaM-KI INa DNA or a polypeptide encoded by the fragment thereof.
  • “specificity” means that an antibody binds to a human CaM-KI INa gene product or fragment.
  • Antibodies against human CaM-KI INa protein can be used in immunohistochemistry to detect human CaM-KI INa protein in biopsy specimens.
  • the invention also relates to a diagnostic test method for quantifying and localizing the level of human CaM-KI INa protein.
  • assays are well known in the art and include FISH assays and radioimmunoassays. The person tested in the test
  • the CaM-KI INa protein level can be used to explain the importance of the human CaM-KI INa protein in various diseases and the disease for diagnosing the action of the CaM-KI INa protein.
  • a method for detecting the presence or absence of a CaM-KIINa protein in a sample is detected by using a specific antibody of the CaM-KIINa protein, which comprises: contacting a sample with a specific antibody against a CaM-KIINa protein; observing whether an antibody complex is formed, forming The antibody complex indicates the presence of the CaM-KIINa protein in the sample.
  • This test can be used as an auxiliary indicator to indicate the degree of differentiation of colon adenocarcinoma.
  • the CaMKIINa polypeptide of the present invention or an agonist thereof or the like can be used for inhibiting the growth of tumor cells (especially colonic adenocarcinoma cells) when administered therapeutically (administered;).
  • these materials can be formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium wherein the pH is usually from about 5 to about 8, preferably from about 6 to about 8, although the pH may be The nature of the formulation and the condition to be treated vary.
  • the formulated pharmaceutical compositions can be administered by conventional routes including, but not limited to, intramuscular, intraperitoneal, intravenous, subcutaneous, intradermal, or topical administration.
  • the CaMKIINa polypeptide or its agonist can be directly used for the treatment of diseases, for example, for the treatment of diseases such as tumors (such as colon adenocarcinoma;
  • diseases such as tumors (such as colon adenocarcinoma;
  • tumors such as colon adenocarcinoma
  • other therapeutic agents can also be used simultaneously.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a safe and effective amount of a CaMKIINa polypeptide of the invention and/or an agonist thereof, and a pharmaceutically acceptable carrier or excipient.
  • Such carriers include, but are not limited to, saline, buffer, dextrose, water, glycerol, ethanol, and combinations thereof.
  • the pharmaceutical formulation should be compatible with the mode of administration.
  • the pharmaceutical compositions of the present invention can be formulated in the form of injections, for example It can be prepared by a conventional method using physiological saline or an aqueous solution containing glucose and other adjuvants.
  • Pharmaceutical compositions such as tablets and capsules can be prepared by a conventional method.
  • Pharmaceutical compositions such as injections, solutions, tablets and capsules are preferably used. Manufactured under sterile conditions.
  • the active ingredient is administered in a therapeutically effective amount, for example about 1 microgram per kilogram of body weight per day to about 5 milligrams per kilogram of
  • a safe and effective amount of the CaMKIINa protein or agonist thereof is administered to the mammal, wherein the safe and effective amount is usually at least about 1 microgram per kilogram of body weight, and in most cases no more than about 8 milligrams per minute. In kilograms of body weight, preferably the dose is from about 10 micrograms per kilogram of body weight to about 1 milligram per kilogram of body weight. Of course, specific doses should also consider factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician.
  • the main advantages of the invention are:
  • CaMKIINa Based on the ability of CaMKIINa polypeptide to inhibit the growth of colonic adenocarcinoma cells, CaMKIINa can be used as an effective tumor therapeutic target and can be used to screen therapeutic agents (caMKIINa agonists) for treating tumors by interacting with CaMKIINa.
  • CaMKIINa can be used as an auxiliary detection marker for indicating the degree of differentiation of colon adenocarcinoma.
  • the invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are merely illustrative of the invention and are not intended to limit the scope of the invention.
  • the experimental methods in the following examples which do not specify the specific conditions are usually carried out according to the conditions described in conventional conditions such as Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer. The suggested conditions.
  • Example 1 Example 1
  • the DNA sequence contained in the new clone was bidirectionally determined by synthesizing a series of primers.
  • This protein was named as Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor a (CaM-KIINa), and its coding gene was named human calcium ion/calmodulin-dependent.
  • sequence SEQ ID NO: 1 is 860 bp in full length (SEQ ID ⁇ : 1) and comprises a 400 bp 5' non-coding region and a 223 bp 3' non-coding region encoding a polypeptide of 78 amino acids (SEQ ID NO: 2).
  • SEQ ID NO: 2 Cloning of the coding sequence of human CaMKIINa protein by RT-PCR
  • the PCR reaction volume was 50 ⁇ 1, including reverse transcription template 10 ⁇ 1, 0.5mM primer, 0.2mM dNTP and 1U rTaq DNA polymerase (Takara), and the amplification parameters were 94°C for 15 seconds, 58°C for 30 seconds, and 72°. C 30 seconds, after 25 cycles, the PCR product was initially confirmed by 1.5% agarose gel electrophoresis.
  • Example 2 the PCR product obtained in Example 2 was used as a template, and amplified with PCR primers at the 5' and 3' ends of the sequence as follows to obtain human CaMKIINa DNA as an insert.
  • the 5' oligonucleotide primer sequence used in the PCR reaction is:
  • the obtained PCR product was purified and digested with BamH I-EcoR I and then with plasmid pGEM-3ZF.
  • the method was recombined and transformed into competent E. coli DH5a, and the positive clones were identified and purified and sequenced (ABI 377 sequencer, BigDye Terminator kit, PE company).
  • the correct sequence of human CaMKIINa cDNA BamH I-EcoR I was cloned into the expression vector pGEX-2T (Pharmacia), and then transformed into E. coli DH5a.
  • the digested products were analyzed by 0.8% agarose gel electrophoresis. It was confirmed by sequencing that the complete CaMKIINa coding sequence has been inserted.
  • the positive DH5a clone expressing CaMKIINa was inoculated in 100 ml of 2xYTA medium, and cultured at 37 ° C for 30-15 rpm for shaking for 12-15 hr, 1:10 diluted in pre-warmed 2xYTA medium, and cultured for 1.5 hr, shaking force 100 mM IPTG to O. lmM After 30 °C induction for 2-6 hr, 5,000 g at 4 ° C, centrifuge for 10 min to remove the supernatant, and resuspend on ice with 50 ml of lxPBS (0.14 M NaCl, 2.7 mM KC1, 10. lmM.
  • the GMKIINa protein was obtained by excision of GST by thrombin (thrombin XSigma), and the molecular weight was about 8 kD.
  • the recombinant human CaMKIINa protein obtained in Example 3 was used to immunize an animal to produce an antibody, and the specific method was as follows.
  • the recombinant molecules are separated by chromatography and used. Separation can also be performed by SDS-PAGE gel electrophoresis, and the electrophoresis band is excised from the gel and emulsified with an equal volume of complete Freund's adjuvant.
  • Mice were intraperitoneally injected with 50-100 g/0.2 ml of emulsified protein. After 14 days, mice were intraperitoneally injected with a dose of 50-100 ⁇ g/0.2 ml with the same antigen emulsified with incomplete Freund's adjuvant to boost the immunization.
  • Immunohistochemical analysis was performed using a tissue microarray (Xi'an Superying Company;) containing normal adult colon tissue and colonic adenocarcinoma tissues of different degrees of differentiation.
  • the dyeing process is in accordance with conventional procedures.
  • Color development according to avidin-biotin The peroxidase complex (ABC) method was performed using a Vectastain Elite ABC kit (; Vector company;).
  • the simple procedure is as follows: First, the tissue chip is baked in a 60-degree incubator for 30 minutes, and then dewaxed and hydrated with xylene and ethanol. The antigen was repaired at a high temperature and pressure of 0.01 M CB (pH 6.0).
  • the endogenous peroxidase was blocked with 0.3% H 2 O 2 , the non-specific site was blocked with non-immune sheep serum, and the endogenous biotin was blocked with a biotin blocking reagent.
  • the anti-CaMKIINa antibody (1:40) obtained in Example 5 was then diluted with the primary antibody dilution in the kit and incubated with the sections overnight at 4 °C.
  • the negative control was replaced with PBS instead of the primary antibody, and the rest of the conditions were the same.
  • PBST containing 0.1% Tween 20 in PBS
  • the HRP-conjugated secondary antibody solution was added dropwise, and allowed to stand at room temperature for 30 min. After washing, it was incubated with ABC Elite reagent for 30 min at room temperature and rinsed with PBS. Observed under the microscope.
  • Example 6 Construction of human CaMKIINa eukaryotic expression vector and transfection of eukaryotic gene
  • Example 2 the PCR product obtained in Example 2 was used as a template, and amplified with PCR primers at the 5' and 3' ends of the sequence below to obtain human CaMKIINa DNA as an insert.
  • the 5' oligonucleotide primer sequence used in the PCR reaction is:
  • the 3' primer sequence is: 5'- T GAA GCT TAC ACC AGG AGG TGC CTT G -3' (SEQ ID NO: 8)
  • the obtained PCR product was purified and digested with EcoR I-Hind III and then eukaryotic expression vector plasmid pcDNA3.1/myc -His (-) B (Invitrogen) was recombined and transformed into competent E. coli DH5a by conventional methods, and positive clones were picked for restriction enzyme digestion, purified and sequenced (ABI's Model 377 Sequencer, BigDye Terminator Kit, PE) the company). It was confirmed by sequencing that the complete CaMKIINa coding sequence has been inserted.
  • the CaMKIINa eukaryotic expression plasmid DNA was transfected into human colon adenocarcinoma LoVo cells by liposome LipofectAMINE (invitrogen); pcDNA3.1 plasmid vector was used as a mock transfection control.
  • the main steps are as follows: The plasmid DNA to be transfected is mixed with liposome LipofectAMINE in a certain ratio and allowed to react at room temperature for 45 minutes; at 60-80% confluent in LoVo cells grown in 6-well cell culture plate, with OPTI-MEM After washing the serum medium (Invitrogen) twice, add the plasmid DNA-liposome mixture, incubate at 37 ° C 5% CO 2 for 6-8 hours, add an equal volume of normal medium containing 20% serum, continue to culture 6 Replace the fresh medium after an hour. Transient expression was collected 48 hours after transfection and subjected to Western blot analysis to detect transfection effects.
  • Example 7 Western blot detection
  • LoVo cells transiently transfected with expression of CaMKIINa protein in Example 7 were lysed with cell lysate (Cell Signaling). The supernatant was taken at 13,000 rpm x lOmin by centrifugation at 4 ° C, and protein quantification was performed using a BCA protein detection kit (; PIERCE). The protein samples were subjected to SDS-PAGE followed by a constant voltage of 100 V at 4 ° C to a nitrocellulose membrane (Schleicher & Schuell), which was stained with Ponceau and marked in size and orientation. Block at room temperature for 2 hours (5% of TBST solution of skimmed milk powder was diluted with blocking solution, and incubated for 1 hour at room temperature.
  • TBST (0.05% Tween 20 in TBS solution) was washed for 15 minutes, 3 times, and the secondary antibody was diluted with blocking solution. Incubate for 2 hours at room temperature. Wash TBST for 15 minutes, 3 times, wash with TBS (10 mM Tris-HCl, pH 8.0, 150 mM NaCl) for 15 minutes, then add chemiluminescent substrate (Pierce) for 1 min, and seal the membrane quickly. And auto-development.
  • the primary antibody used for Western blot detection was the anti-CaMKIINa antibody obtained in Example 5.
  • the secondary antibody was HRP-labeled anti-rabbit IgG (Cell Signaling).
  • LoVo cells overexpressing the CaMKIINa protein in Example 6 in the logarithmic growth phase were seeded in a 96-well flat-bottomed plate, and each of the three wells was placed and cultured at 37 ° C, 5% CO 2 .
  • 10% MTT (5mg/ml, Sigma) medium 100 ⁇ 1 continue to incubate for 4 hours, carefully aspirate the supernatant and then add 150 ⁇ 1/well DMSO, incubate at 37 °C for 10 minutes to dissolve intracellular forasia (foraiazan), using enzyme-linked
  • the instrument measures the OD value at a wavelength of 570 nm.
  • Example 9 Establishment of a human colon cancer xenograft model and observation of CaMKIINa anti-tumor effect Under sterile experimental conditions, nude mice (Balb/c nude mice, male, 4-5 weeks old, Chinese Academy of Sciences;) LoVo cells grown in the right side of the left forelimb were injected subcutaneously with 2 ⁇ 10 6 cells/nose in nude mice, and local visceral lesions were observed to observe the tumor growth. The nodules usually appear after 3-4 days, that is, the establishment of the transplanted tumor model.
  • Nude mice with a tumor size of 3-4 mm were selected from the mice modeled as LoVo cell xenografts and randomly divided into three groups of 6 rats: (1) CaMKIIN (group X: 20 g of CaMKIIN injected intratumorally) Oc eukaryotic recombinant plasmid; (2) empty vector pcDNA3.1/myc-His (-) B mock control group: intratumor injection of 20 g of empty vector plasmid; (3) PBS control group: intratumoral injection 2 ( ⁇ 1 PBS; Immediately after the injection of each group, the plasmid DNA was introduced into the tumor tissue by the « « vivo electroporation electric pulse (300V, 960 ⁇ ) gene introduction method ( ⁇ 830 electroporator).
  • the tumor growth was observed dynamically during the experiment.
  • the maximum diameter a and the transverse b were measured with vernier calipers every three days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un nouvel inhibiteur a de la protéine kinase II humaine dépendant du calcium/de la calmoduline (CaM-KIINa). L'invention concerne aussi l'utilisation de CaM-KIINa et de la séquence codante de celui-ci. La protéine de l'invention est un inhibiteur a de la protéine kinase II dépendant du calcium/de la calmoduline, qui est exprimé à un faible niveau dans l'adénocarcinome malin du côlon peu différencié et inhibe manifestement la croissance de cellules d'adénocarcinome du côlon.
PCT/CN2007/070629 2007-09-05 2007-09-05 Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline Ceased WO2009030088A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070629 WO2009030088A1 (fr) 2007-09-05 2007-09-05 Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070629 WO2009030088A1 (fr) 2007-09-05 2007-09-05 Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline

Publications (1)

Publication Number Publication Date
WO2009030088A1 true WO2009030088A1 (fr) 2009-03-12

Family

ID=40428439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/070629 Ceased WO2009030088A1 (fr) 2007-09-05 2007-09-05 Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline

Country Status (1)

Country Link
WO (1) WO2009030088A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120665206A (zh) * 2025-08-18 2025-09-19 昆明医科大学第一附属医院(云南省皮肤病医院) 一种结直肠癌抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1603341A (zh) * 2003-09-29 2005-04-06 第二军医大学免疫学研究所 人钙离子/钙调蛋白依赖性蛋白激酶II抑制性蛋白α，其编码序列及用途
WO2006017443A2 (fr) * 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Composes a base de pyrrolopyrimidine a substitution arylamine inhibiteurs de kinases multiples

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1603341A (zh) * 2003-09-29 2005-04-06 第二军医大学免疫学研究所 人钙离子/钙调蛋白依赖性蛋白激酶II抑制性蛋白α，其编码序列及用途
WO2006017443A2 (fr) * 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Composes a base de pyrrolopyrimidine a substitution arylamine inhibiteurs de kinases multiples

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120665206A (zh) * 2025-08-18 2025-09-19 昆明医科大学第一附属医院(云南省皮肤病医院) 一种结直肠癌抗体及其应用
CN120665206B (zh) * 2025-08-18 2025-10-31 昆明医科大学第一附属医院(云南省皮肤病医院) 一种结直肠癌抗体及其应用

Similar Documents

Publication Publication Date Title
JP2001504333A (ja) 前立腺特異カリクレイン
JP2002507124A (ja) ヒト細胞外基質タンパク質
JP2001515349A (ja) Ｔｍ４ｓｆヒト腫瘍関連抗原
JP2002502242A (ja) ユビキチン結合タンパク質
JP2001517943A (ja) ヒト膵炎関連タンパク質、ｐａｐ−２
JP2001514657A (ja) 成長因子受容体結合タンパク質
JP2001509018A (ja) Ｐ５３応答マウス遺伝子ｅｉ１２４に類似なｄｎａがコードするヒトアポトーシス関連タンパク質
JP2001503628A (ja) 新規なヒスタミンｈ２受容体
JPH11503904A (ja) セルブレビン・ホモログ
JP2001525675A (ja) 腫瘍関連抗原
JP2002534088A (ja) インスリン合成遺伝子
WO2009030088A1 (fr) Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline
JP2001513640A (ja) 新規なヒト膜貫通４スーパーファミリータンパク質
JP2002501378A (ja) ヒト腫瘍関連Ｋａｚａｌインヒビタ
JP2002527028A (ja) ヒトアポトーシス調節タンパク質
AU2003231196C1 (en) Androgen-regulated PMEPA1 and cancer
JP2002186492A (ja) ヒトｒｃｅ１
CN100480264C (zh) 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列
JP2001517945A (ja) ヒト腫瘍形成関連タンパク質、ｈｔａｐ
JP2001517940A (ja) セリン／スレオニンプロテインキナーゼ
JP2001521385A (ja) ヒト腫瘍関連膜タンパク質
WO2009030094A1 (fr) Fonction et utilisation d'une nouvelle protéine induisant une apoptose associée aux lysosomes contenant les domaines ph et fyve (lapf)
CN100415299C (zh) 胚泡着床相关因子及其用途
WO2009030087A1 (fr) Fonctions et utilisations de la protéine 4 se liant à la phosphatidyléthanolamine
CN100384481C (zh) 胚泡着床相关因子及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801038

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07801038

Country of ref document: EP

Kind code of ref document: A1